EcoDrugPlus

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSAPOG00000018936
Gene Symbol: LOC110956697
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSAPOG00000022997
Gene Symbol: MAPK10
2 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase 10-Like

Ensembl ID : ENSAPOG00000002720
Gene Symbol: LOC110962918
3 Cross references
179 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSAPOG00000015032
Gene Symbol: LOC110947990
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSAPOG00000006083
Gene Symbol: MAPK14
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSAPOG00000016559
Gene Symbol: LOC110956114
3 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSAPOG00000013538
Gene Symbol: LOC110959104
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a-Like

Ensembl ID : ENSAPOG00000001043
Gene Symbol: LOC110967601
3 Cross references
223 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSAPOG00000009700
Gene Symbol: MAPK9
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSAPOG00000008515
Gene Symbol: MAP2K1
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSAPOG00000016712
Gene Symbol: MAP3K10
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11-Like

Ensembl ID : ENSAPOG00000016663
Gene Symbol: LOC110962013
2 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).